Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin® (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment...
More...
Linear Mode
